Eisai is a global leading research-based pharmaceutical company driven by “giving first thought to patients and their families and increasing the benefits that health care provides”. Eisai is committed to research and development and has an exciting pipeline from new discoveries, acquired molecules and further development of licensed products within Neurology, Gastroenterology, Critical Care and
Oncology. With operations in U.S., Asia, Europe and the domestic market of Japan, Eisai employs 11.000 people worldwide. The Nordic headquarter is in Sweden, Danderyd, north of Stockholm.
Further information about the company in Europe can be found on http://www.eisai.co.uk.
Oncology. With operations in U.S., Asia, Europe and the domestic market of Japan, Eisai employs 11.000 people worldwide. The Nordic headquarter is in Sweden, Danderyd, north of Stockholm.
Further information about the company in Europe can be found on http://www.eisai.co.uk.
Key Account Manager - Neurology
- working with Eisai´s neurology portfolio
Experience and qualifications required
We are looking for an experienced Sales professional with a successful history in pharmaceutical sales and with a good understanding of the Swedish healthcare environment. The right candidate have a good understanding and evidence of a successful KAM approach to business. We would like the candidate to have secondary care pharmaceutical sales background, preferably in the area of neurology.
The position
The Key Account Manager will have full responsibility for sales of the Epilepsy portfolio in North of Sweden (Stockholm and further north) with a special focus on Fycompa®. The position holds full responsibility to develop and execute the Key Account strategy and achieve targets and related Key Performance Indicators (KPIs). This means to independently make sales calls, plan and execute
activities, and to build and maintain good business relationships with customers and Key Opinion Leaders in the area of Epilepsy.
The position is field based and reports to the Sales Manager in Sweden & Norway. The role require travelling mainly within the designated Territory but might also involve travelling within the Nordic region.
Territorial responsibility
Responsibility for Neurology in Sweden is shared with a colleague in the South. This role holds the responsibility for North of Sweden (Stockholm, Linköping, Uppsala, Västerås, Örebro, Karlstad, Umeå, Gävle, Sundsvall) and is preferably based in the “Mälardalen”.
About Neurology
Eisai has a unique position in Epilepsy with two products on the market and is fully committed to maintaining a long-term position in the area of Neurology.
Epilepsy
Inovelon® (rufinamide) – adjunctive therapy in the treatment of seizures associated with LennoxGastaut syndrome in patients from1 year and older.
Fycompa® (perampanel) first-in-class AMPA receptor antagonist, for adjunctive treatment of focal seizures, with or without secondary generalisation, in patients from 4 years of age and in primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy in patients from 7years of age.
Alzheimer´s disease
Eisai has a very interesting pipeline within dementia with compounds for Alzheimer’s disease in different stages of clinical development.
Lecanemab - an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s Disease (AD). Eisai submitted a marketing authorization application for lecanemab to the European Medicines Agency in January 2023. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study (Study 201), which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.
Contact
For inquires and more information about the position, please contact Jarl Molin, Recruitment Consultant at PeakSearch.
e-mail: jarl.molin@peaksearch.se; mobile: +46 (0)70-560 20 56
We are looking for an experienced Sales professional with a successful history in pharmaceutical sales and with a good understanding of the Swedish healthcare environment. The right candidate have a good understanding and evidence of a successful KAM approach to business. We would like the candidate to have secondary care pharmaceutical sales background, preferably in the area of neurology.
The position
The Key Account Manager will have full responsibility for sales of the Epilepsy portfolio in North of Sweden (Stockholm and further north) with a special focus on Fycompa®. The position holds full responsibility to develop and execute the Key Account strategy and achieve targets and related Key Performance Indicators (KPIs). This means to independently make sales calls, plan and execute
activities, and to build and maintain good business relationships with customers and Key Opinion Leaders in the area of Epilepsy.
The position is field based and reports to the Sales Manager in Sweden & Norway. The role require travelling mainly within the designated Territory but might also involve travelling within the Nordic region.
Territorial responsibility
Responsibility for Neurology in Sweden is shared with a colleague in the South. This role holds the responsibility for North of Sweden (Stockholm, Linköping, Uppsala, Västerås, Örebro, Karlstad, Umeå, Gävle, Sundsvall) and is preferably based in the “Mälardalen”.
About Neurology
Eisai has a unique position in Epilepsy with two products on the market and is fully committed to maintaining a long-term position in the area of Neurology.
Epilepsy
Inovelon® (rufinamide) – adjunctive therapy in the treatment of seizures associated with LennoxGastaut syndrome in patients from1 year and older.
Fycompa® (perampanel) first-in-class AMPA receptor antagonist, for adjunctive treatment of focal seizures, with or without secondary generalisation, in patients from 4 years of age and in primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy in patients from 7years of age.
Alzheimer´s disease
Eisai has a very interesting pipeline within dementia with compounds for Alzheimer’s disease in different stages of clinical development.
Lecanemab - an investigational anti-amyloid beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s Disease (AD). Eisai submitted a marketing authorization application for lecanemab to the European Medicines Agency in January 2023. This application is based on the results of the Phase III Clarity AD study and the Phase IIb clinical study (Study 201), which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD.
Contact
For inquires and more information about the position, please contact Jarl Molin, Recruitment Consultant at PeakSearch.
e-mail: jarl.molin@peaksearch.se; mobile: +46 (0)70-560 20 56